|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005821,
umls-concept:C0008976,
umls-concept:C0010181,
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0027051,
umls-concept:C0030705,
umls-concept:C0070166,
umls-concept:C0302350,
umls-concept:C0522523,
umls-concept:C0948089,
umls-concept:C1274040,
umls-concept:C1301732,
umls-concept:C1516048,
umls-concept:C1522318,
umls-concept:C1620287,
umls-concept:C1948041
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-1-5
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
In patients with acute coronary syndromes and planned percutaneous coronary intervention, the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) demonstrated that treatment with prasugrel versus clopidogrel was associated with reduced rates of cardiovascular death, MI, or stroke and an increased risk of major bleeding. We evaluated the cost-effectiveness of prasugrel versus clopidogrel from the perspective of the US healthcare system by using data from TRITON-TIMI 38.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1524-4539
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
5
|
|
pubmed:volume |
121
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
71-9
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:20026770-Acute Coronary Syndrome,
pubmed-meshheading:20026770-Angioplasty, Balloon, Coronary,
pubmed-meshheading:20026770-Combined Modality Therapy,
pubmed-meshheading:20026770-Cost-Benefit Analysis,
pubmed-meshheading:20026770-Databases, Factual,
pubmed-meshheading:20026770-Drug Costs,
pubmed-meshheading:20026770-Follow-Up Studies,
pubmed-meshheading:20026770-Hemorrhage,
pubmed-meshheading:20026770-Hospitalization,
pubmed-meshheading:20026770-Humans,
pubmed-meshheading:20026770-Life Expectancy,
pubmed-meshheading:20026770-Multicenter Studies as Topic,
pubmed-meshheading:20026770-Myocardial Infarction,
pubmed-meshheading:20026770-Outcome and Process Assessment (Health Care),
pubmed-meshheading:20026770-Piperazines,
pubmed-meshheading:20026770-Platelet Aggregation Inhibitors,
pubmed-meshheading:20026770-Randomized Controlled Trials as Topic,
pubmed-meshheading:20026770-Stroke,
pubmed-meshheading:20026770-Thiophenes,
pubmed-meshheading:20026770-Thrombolytic Therapy,
pubmed-meshheading:20026770-Ticlopidine,
pubmed-meshheading:20026770-United States
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.
|
|
pubmed:affiliation |
Saint Luke's Mid America Heart Institute, 4401 Wornall Rd, Kansas City, MO 64111, USA. emahoney1@saint-lukes.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
